Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government

被引:0
|
作者
Karel H. van der Pol
Mohamad Aljofan
Olivier Blin
Jan H. Cornel
Gerard A. Rongen
Aurélie-Gaëlle Woestelandt
Michael Spedding
机构
[1] Radboud University Medical Center,Department of Internal Medicine, Radboud Institute for Health Sciences
[2] Nazarbayev University School of Medicine,Department of Biomedical Science
[3] National Laboratory Astana,Institut de Neurosciences des Systèmes
[4] Nazarbayev University,Department of Cardiology, Radboud Institute for Health Sciences
[5] Aix Marseille Université,Department of Cardiology
[6] Inserm UMR 1106,undefined
[7] Radboud University Medical Center,undefined
[8] Northwest Clinics,undefined
[9] Spedding Research Solutions SAS,undefined
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Drug repurposing is the process of identifying a new use for an existing drug or active substance in an indication outside the scope of the original indication. Drug repurposing has important advantages including reduced development time and costs, and potentially large societal healthcare cost savings. However, current generic drug repurposing research faces a number of challenges in obtaining research funds. Furthermore, regardless of the success of a repurposing trial, commercial parties often lack interest in pursuing marketing authorisation for financial reasons, and academic researchers lack the knowledge, time and funding. Therefore, the new indication of a repurposed drug often does not make it ‘on label’. We propose a large increase in public funding for generic drug repurposing research, including funds for the marketing authorisation process when a trial is successful, and a reduction in the regulatory burden of the marketing authorisation process for repurposed generic drugs.
引用
收藏
页码:831 / 840
页数:9
相关论文
共 50 条
  • [21] Generic Substitution of Orphan Drugs for the Treatment of Rare Diseases: Exploring the Potential Challenges
    Di Paolo, Antonello
    Arrigoni, Elena
    DRUGS, 2018, 78 (04) : 399 - 410
  • [22] The Role of Dopamine in Repurposing Drugs for Oncology
    Moura, Catarina
    Vale, Nuno
    BIOMEDICINES, 2023, 11 (07)
  • [23] MicroRNA-Mediated Drug Repurposing Unveiled Potential Candidate Drugs for Prolactinoma Treatment
    Aydin, Busra
    Arslan, Sema
    Bayrakli, Fatih
    Karademir, Betul
    Arga, Kazim Yalcin
    NEUROENDOCRINOLOGY, 2022, 112 (02) : 161 - 173
  • [24] Drug Repurposing for Schistosomiasis: Combinations of Drugs or Biomolecules
    Gouveia, Maria Joao
    Brindley, Paul J.
    Gartner, Fatima
    Correia da Costa, Jose M.
    Vale, Nuno
    PHARMACEUTICALS, 2018, 11 (01)
  • [25] New drugs and drug repurposing for hidradenitis suppurativa
    Zouboulis, Christos C.
    Zouboulis, Viktor A.
    Zouboulis, Konstantin C.
    EXPERIMENTAL DERMATOLOGY, 2022, 31 : 116 - 118
  • [26] Drug repurposing: new tricks for old drugs
    Gayaparsad, M.
    SOUTHERN AFRICAN JOURNAL OF ANAESTHESIA AND ANALGESIA, 2022, 28 (05) : S127 - S131
  • [27] Drug repurposing: Iron in the fire for older drugs
    Sonaye, H. V.
    Sheikh, R. Y.
    Doifode, C. A.
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 141
  • [28] Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements
    Frega, Giorgio
    Palloni, Andrea
    Di Pasquale, Giuseppe
    Saccoccio, Gioconda
    Rizzo, Alessandro
    Poluzzi, Elisabetta
    Iannone, Primiano
    Brandi, Giovanni
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [29] Old drugs, new tricks: Emerging role of drug repurposing in the management of atopic dermatitis
    Prasannanjaneyulu, Velpula
    Nene, Shweta
    Jain, Harsha
    Nooreen, Rimsha
    Otavi, Shivam
    Chitlangya, Palak
    Srivastava, Saurabh
    CYTOKINE & GROWTH FACTOR REVIEWS, 2022, 65 : 12 - 26
  • [30] New government drug repurposing programs: Opportunities and uncertainties
    Liddicoat, Johnathon
    Hamidzadeh, Ashleigh
    Liddell, Kathleen
    Schito, Marco
    Simon, David
    Aboy, Mateo
    Minssen, Timo
    SCIENCE TRANSLATIONAL MEDICINE, 2024, 16 (753)